Search results for: 'long term impacts of evolving cloud'

26 Aug 2024  |  Global  |  Market Research

Growth Opportunities in the Tissue Diagnostics Industry, Global, 2024 2029

Companion Diagnostics-specific Advanced Staining and Multiomics Capabilities are Driving Market Growth

Infographics

×

The global tissue diagnostics market will experience significant growth driven by the need for advanced staining in precise biomarker identification in personalized medicine, tissue biopsy test volumes, and pre-analytical and advanced staining platform development. According to the WHO, there will be a 60% rise in cancer cases worldwide by 2040,...

23 May 2017  |  North America  |  Market Research

Growth Opportunities in the US In Vitro Diagnostics (IVD) Market, Forecast to 2021

US IVD Market Witnesses Pricing Fluctuations Due to the PAMA Regulation

Infographics

×

The In Vitro Diagnostics (IVD) landscape in the United States is extremely dynamic, with a high level of merger and acquisition activity with many high-value deals still pending. Both clinical laboratories and manufacturers are increasingly vying for smaller specialized niche technology companies to increase their market share. Molecular point of c...

17 Jul 2017  |  North America  |  Market Research

US Oncology Diagnostics Market, Forecast to 2021

Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection

Infographics

×

Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolida...

23 Aug 2018  |  Europe  |  Market Research

Western European Clinical Laboratory Services Market, Forecast to 2022

Clinical Labs to Transform into Health Information Companies and Increasingly Participate in Clinical Decision Support

Infographics

×

Key Issues Addressed

Diagnostics has inarguably become an integral part of healthcare system, moving from reactionary science to predictive science; playing a vital role throughout the care continuum. While rising burden of chronic diseases, drug-resistant diseases and the increasing proportion of elderly population are the organic growth drivers, the shift towards cre...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2018 that centered around the state of their laboratories in 2018 and their expectations for 2019. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-o...

The Healthcare industry has witnessed some of the largest mega-mergers in 2018 – mergers on the provider as well as the payer ends. While this has the potential to bring a shift in power centers in the ecosystem, each stakeholder has relied heavily on inorganic growth to maintain their stronghold. This Mergers and Acquisitions in Life Sciences Indu...

20 Mar 2019  |  North America  |  Market Research

Growth Opportunities in the North American Clinical Laboratory Services Market, Forecast to 2022

Laboratories Seek Alternate Revenue Streams to Combat Reimbursement Pressure

Infographics

×

Clinical laboratory services represent one of the highest healthcare expenditures in North America, yet the United States and Canada represent different scenarios in the way clinical services are rendered. The market for clinical lab services in Canada was an estimated $10.33 billion in 2017 whereas in the United States it was an estimated $78.33 b...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-ove...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...